Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Current ratio
Zoetis Inc.'s current ratio at the end of the quarter to 30 June 2026 was 3.1×, up 0.1× from fiscal 2025 (3.0×). Over the past ten years it has ranged from 1.8× (fiscal 2024) to 3.9× (fiscal 2021); the current reading is higher than 45% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.3× and in line with the Healthcare sector median of 3.0×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.0× | 72.61% |
| FY2024 | 1.8× | (47.75%) |
| FY2023 | 3.4× | 41.68% |
| FY2022 | 2.4× | (38.54%) |
| FY2021 | 3.9× | 26.58% |
| FY2020 | 3.0× | 15.88% |
| FY2019 | 2.6× | (26.91%) |
| FY2018 | 3.6× | (6.69%) |
| FY2017 | 3.9× | 27.01% |
| FY2016 | 3.0× | 41.13% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.1× | (2.20%) |
| Mar 2026 | 3.2× | 1.17% |
| Dec 2025 | 3.1× | (14.44%) |
| Sep 2025 | 3.6× | 107.03% |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| UTHR United Therapeutics Corporation compare | 5.7× |
| ZTS Zoetis Inc. | 3.1× |
| ELAN Elanco Animal Health Incorporated compare | 2.1× |
| RDY Dr. Reddy's Laboratories Ltd compare | 1.9× |
| NBIX Neurocrine Biosciences, Inc. compare | 1.9× |
| VTRS Viatris Inc. compare | 1.6× |
| TAK Takeda Pharmaceutical Co. compare | 1.1× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 0.9× |
| HLN Haleon PLC Sponsored ADR compare | 0.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.3× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement